Ambrisentan (Letairis®) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Pulmonologist or Cardiologist

- AND -

- Diagnosis of pulmonary arterial hypertension World Health Organization [WHO] Group I with WHO/New York Heart Association Functional Class II, III or IV

- AND -

- Patient is NOT diagnosed with idiopathic pulmonary fibrosis

- Dose Change Only: Patient previously met criteria and is already taking the drug.

Notes:

Ambrisentan is teratogenic and should not be used in pregnant females

Ambrisentan is not recommended in patients with moderate (Child-Pugh Class B) to severe (Child-Pugh Class C) hepatic impairment or in patients with AST/ALT greater than 3 times the upper limit of normal

Ambrisentan is available through a restricted risk evaluation and mitigation strategy (REMS) program